Who is sponsoring NCT00538187?

NCT00538187 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT00538187?

Interventions in NCT00538187: obatoclax mesylate, bortezomib, laboratory biomarker analysis, pharmacological study.

What condition does NCT00538187 study?

NCT00538187 studies Adult Non-Hodgkin Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma.

Is NCT00538187 still recruiting?

NCT00538187 is currently terminated. Last updated 3 December 2015.

Last reviewed 2015-12-03 · How we verify

NCT00538187

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study of GX15-070 (NSC # 729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma

Terminated Phase 1 Last updated 3 December 2015

What this trial tests

Phase 1 trial testing obatoclax mesylate in Adult Non-Hodgkin Lymphoma in 18 participants. Terminated before completion.

Timeline

1 December 2007

Primary endpoint
1 April 2011

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	1 December 2007
Primary completion	1 April 2011
Sites	1 location across United States

Drugs / interventions tested

obatoclax mesylate — full drug profile →
bortezomib (bortezomib) — full drug profile →
laboratory biomarker analysis — full drug profile →
pharmacological study — full drug profile →

Conditions studied

Adult Non-Hodgkin Lymphoma — all drugs for Adult Non-Hodgkin Lymphoma →
Recurrent Adult Diffuse Large Cell Lymphoma — all drugs for Recurrent Adult Diffuse Large Cell Lymphoma →
Recurrent Grade 1 Follicular Lymphoma — all drugs for Recurrent Grade 1 Follicular Lymphoma →
Recurrent Grade 2 Follicular Lymphoma — all drugs for Recurrent Grade 2 Follicular Lymphoma →

Sponsor

National Cancer Institute (NCI)

Who can join

18 and older, any sex, with Adult Non-Hodgkin Lymphoma or Recurrent Adult Diffuse Large Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Maximum tolerated dose of obatoclax mesylate when administered with bortezomib
Time frame: 35 days
Defined as the highest dose tested in which fewer than 33% of patients experienced DLT attributable to the study drug(s), when at least six patients were treated at that dose and are evaluable for toxicity. Graded according to the NCI CTCAE, Version 3.0.

Sponsor's own description

Obatoclax may stop the growth of non-Hodgkin lymphoma by blocking blood flow to the cancer. Bortezomib and obatoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obatoclax together with bortezomib may kill more cancer cells. This phase I/II trial is studying the side effects and best dose of obatoclax when given together with bortezomib and to see how well they work in treating patients with aggressive relapsed or recurrent non-Hodgkin lymphoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Ionophores: Potential Use as Anticancer Drugs and Chemosensitizers.
Kaushik V, Yakisich JS, Kumar A, Azad N, et al · · 2018 · cited 58× · PMID 30262730 · DOI 10.3390/cancers10100360
BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.
Silva JPN, Pinto B, Silva PMA, Bousbaa H. · · 2026 · cited 1× · PMID 41596764 · DOI 10.3390/ijms27021123

Verify or expand the search:

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00538187 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 3 December 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00538187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing